Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Third Harmonic Bio, Inc. (THRD)
NASDAQ:THRD
RESEARCH TOOLSreports
Third Harmonic Bio, Inc. (THRD) Stock Price & Analysis
13 Followers
THRD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.33 - $13.68
Previous Close$12.92
Volume142.00K
Average Volume (3M)151.98K
Market Cap
$526.58M
Enterprise Value$261.46M
Total Cash (Recent Filing)$269.07M
Total Debt (Recent Filing)$3.95M
Price to Earnings (P/E)-17.4
Beta0.71
Next Earnings
Aug 08, 2024EPS Estimate
-$0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.74
Shares Outstanding40,714,399
10 Day Avg. Volume90,014
30 Day Avg. Volume151,982
Standard Deviation0.27
R-Squared0.23
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.95
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-23.40
P/FCF Ratio150.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-11.68
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering2
Third Harmonic Bio, Inc. News
PremiumCompany Announcements
Third Harmonic Bio Releases New Corporate Presentation
PremiumCompany Announcements
Third Harmonic Bio Welcomes New Director, Geoff McDonough
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentA Phase I study of THB335, a next-gen KIT inhibitor, has begun with the potential for positive data influencing future studies.
Market OpportunityThe worldwide opportunity for the treatment could be greater than $2.5 billion at peak in the chronic spontaneous urticaria indication.
Safety ProfileAdditional preclinical data suggests THB335 may avoid the safety issues seen with THB001, potentially offering a better safety profile.
Bears Say
Clinical TrialsPhase 1b study with THB001 was discontinued due to safety concerns regarding liver toxicity.
Drug DevelopmentTwo cases of transaminitis were found in the initial Ph. Ib proof-of-concept study, resulting in the discontinuation of the trial and development of THB001.
EarningsTHRD reported a Q1 net loss of $7.9MM.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
THRD FAQ
What was Third Harmonic Bio, Inc.’s price range in the past 12 months?
Third Harmonic Bio, Inc. lowest stock price was $4.33 and its highest was $13.68 in the past 12 months.
What is Third Harmonic Bio, Inc.’s market cap?
Currently, no data Available
When is Third Harmonic Bio, Inc.’s upcoming earnings report date?
Third Harmonic Bio, Inc.’s upcoming earnings report date is Aug 08, 2024 which is in 83 days.
How were Third Harmonic Bio, Inc.’s earnings last quarter?
Third Harmonic Bio, Inc. released its earnings results on May 15, 2024. The company reported $0.2 earnings per share for the quarter, beating the consensus estimate of -$0.31 by $0.51.
Is Third Harmonic Bio, Inc. overvalued?
According to Wall Street analysts Third Harmonic Bio, Inc.’s price is currently Overvalued.
Does Third Harmonic Bio, Inc. pay dividends?
Third Harmonic Bio, Inc. does not currently pay dividends.
What is Third Harmonic Bio, Inc.’s EPS estimate?
Third Harmonic Bio, Inc.’s EPS estimate is -$0.32.
How many shares outstanding does Third Harmonic Bio, Inc. have?
Third Harmonic Bio, Inc. has 40,756,830 shares outstanding.
What happened to Third Harmonic Bio, Inc.’s price movement after its last earnings report?
Third Harmonic Bio, Inc. reported an EPS of $0.2 in its last earnings report, beating expectations of -$0.31. Following the earnings report the stock price went up 0.077%.
Which hedge fund is a major shareholder of Third Harmonic Bio, Inc.?
Among the largest hedge funds holding Third Harmonic Bio, Inc.’s share is RA Capital Management. It holds Third Harmonic Bio, Inc.’s shares valued at 22M.
---
Third Harmonic Bio, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Bullish
THRD Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
182.71%
12-Months-Change
Fundamentals
Return on Equity
-10.84%
Trailing 12-Months
Asset Growth
-7.16%
Trailing 12-Months
Company Description
Third Harmonic Bio, Inc.
Third Harmonic Bio Inc is a clinical-stage company developing a novel oral approach to the treatment of severe allergy and inflammation. The company's lead product candidate, THB001, is a highly selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival.
---
THRD Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering THRD
1 Year
1 Year Success Rate
4/6 ratings generated profit
1 Year Average Return
+40.32%
reiterated a buy rating yesterday
Copying Sam Slutsky's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +40.32% per trade.
---